Related Experiment Video
Updated: Sep 27, 2025
Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
High Expression of PEA15 Is Associated With Patient Survival in Malignant Pleural Mesothelioma
Shajedul Islam1,2, Takao Kitagawa1, Yasuhiro Kuramitsu1
1Advanced Research Promotion Center, Health Sciences University of Hokkaido, Hokkaido, Japan.
Background/Aim:
Malignant pleural mesothelioma (MPM) is a rare but very aggressive tumor that is primarily pleural in origin. The 5-year overall survival rate of patients with MPM has not improved despite therapeutic advances. Therefore, biomarker discovery to identify premalignant or early malignant tumors of the mesothelium are crucial. PEA15 is a cytoplasmic protein that is involved in various human malignancies, including MPM. However, the clinicopathological involvement of PEA15 in MPM has not yet been documented.
Materials And Methods:
The Oncomine database and GEPIA2 platform were used to analyze PEA15 mRNA expression and patient survival in patients with MPM.
Results:
PEA15 was found to be significantly up-regulated in MPM, and this up-regulation inversely correlated with prolonged patient survival. Further, PEA15 expression was found to be increased in other cancer tissues without affecting overall survival.
Conclusion:
PEA15 may represent a new potential prognostic biomarker in MPM patients.
Insights
PEA15 protein is elevated in malignant pleural mesothelioma (MPM), an aggressive cancer. Higher PEA15 levels correlate with poorer survival, suggesting its potential as a prognostic biomarker for MPM patients.
Area of Science:
- Oncology
- Molecular Biology
- Biomarker Discovery
Background:
- Malignant pleural mesothelioma (MPM) is a rare, aggressive cancer with poor prognosis.
- Current therapeutic advances have not improved survival rates for MPM.
- Biomarker discovery is crucial for early detection and improved patient outcomes.
Purpose of the Study:
- To investigate the clinicopathological role of PEA15 in MPM.
- To determine if PEA15 expression correlates with patient survival in MPM.
Main Methods:
- Analysis of PEA15 mRNA expression using the Oncomine database.
- Evaluation of PEA15 and patient survival data via the GEPIA2 platform.
Main Results:
- PEA15 is significantly upregulated in MPM tissues.
- Increased PEA15 expression is inversely correlated with prolonged patient survival in MPM.
- PEA15 expression is elevated in other cancers, but without impacting overall survival.
Conclusions:
- PEA15 may serve as a novel prognostic biomarker for malignant pleural mesothelioma.
- Further research is warranted to explore PEA15's therapeutic potential in MPM.
More Related Videos
07:54Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
Published on: December 21, 2019
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
